Carfilzomib

DCTPepD ID  DCTPepD0012

Active Ingredients   Carfilzomib

Description  An epoxomicin derivate with potential antineoplastic activity. Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.

Synonyms  Kyprolis; PR-171; (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide; Carfilzomib

Disease  Relapsed multiple myeloma

Classification

  

Proteasome inhibitor Peptide and derivative

Structure Information


Molecular Formula  C40H57N5O7

Molecular Weight  719.924

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide

InChI  InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

InChI_Key BLMPQMFVWMYDKT-NZTKNTHTSA-N

SMILES  O=C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CC(C)C)C([C@@]1(C)CO1)=O)=O)CC2=CC=CC=C2)=O)=O)CCC3=CC=CC=C3)CN4CCOCC4

External Codes


PubChem CID  11556711

DrugBank Accession Number  DB08889

NCI Thesaurus Code  C52196  

UNII  72X6E3J5AR   GSRS

CAS  868540-17-4



Drug approval


Drug indication
    Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Kyprolis 30 mg/vial; 60 mg/vial Powder; Intravenous Onyx Therap Prescription NDA: 202714 2012
Kyprolis 60 mg/vial Powder; Intravenous Amgen Canada Inc Prescription DIN: 02451034 2016
Kyprolis 10 mg/vial Powder; Intravenous Amgen Canada Inc Prescription DIN: 02459930 2017
Kyprolis 30 mg/vial Powder; Intravenous Amgen Canada Inc Prescription DIN: 02459949 2017

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01775553 Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib Relapse Multiple Myeloma; Refractory Multiple Myeloma Phase 2 Treatment
NCT02257476 A Phase I Study of Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Malignancies Neoplasms; Malignancies Phase 1 Treatment
NCT02145403 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies Hematologic Malignancies ; Relapse; Graft-Versus-HostDisease Phase 1/2 Treatment
NCT02142530 Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Peripheral T-cell Lymphoma Phase 1 Treatment
NCT01926665 Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Patients With Mantle Cell (MCL), T-cell (TCL), and Diffuse B-Cell Lymphoma (DLBCL) Lymphoma Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.